Portal de recerca
Mejoras clínicas después del cambio guiado por farmacocinética de factores de coagulación de media vida estándar a factores de media vida extendida.
Dades bàsiques
- Protocol:
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2022
- Any de finalització:
- 2024
Documents
- No hi ha documents
Participants
Grups d'Investigació
Resultats de l'Assaig Clínic
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
A post hoc comparative real-world analysis of HEAD-US score for joint health assessment of patients with severe haemophilia A and B in Spain
Alvarez-Roman, Maria Teresa; (...); Kim, Hae Kyung
Article. 10.1111/hae.14924. 2024
Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.
Pérez-Alenda S; (...); Núñez-Cortés R
Article. 10.1111/hae.14988. 2024
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
Article. 10.3389/fimmu.2023.1171065. 2023
Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types
Jimenez-Yuste, Victor; (...); Kim, Hae Kyung
Letter. 10.1016/j.rpth.2023.102207. 2023
Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort.
Sarmiento Doncel, Samuel; (...); Lopez Guerrero, Jose A
Article. 10.3390/life14081041. 2024
Delving into the clinical impact of NETs in pediatric cancer.
Benavent N; (...); Medina P
Article. 10.1038/s41390-024-03437-4. 2024
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
Fischer K; (...); Königs C
Article. 10.1182/bloodadvances.2023011442. 2024
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
DIAGNOSIS OF JOINT BLEEDS: PREDICTIVE MODELING BASED ON PATIENT-REPORTED SYMPTOMS
Goldmann, G.; (...); Tiede, A.
Meeting Abstract. 2023
Effectiveness of progressive moderate-vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with haemophilia: secondary analysis of a randomized controlled trial.
Cruz-Montecinos C; (...); Calatayud J
Article. 10.1111/ejh.13900. 2022
EFFECTS OF MULTIMODAL EXERCISES PROGRAM ON BALANCE, FUNCTIONALITY, RISK OF FALLS AND STRENGTH IN PEOPLE WITH HAEMOPHILIA
Chimeno-Hernandez, A.; (...); Querol, F.
Article. 2022
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES
Miesbach, W.; (...); Mahlangu, J.
Meeting Abstract. 2023
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
EPTACOG BETA EFFICACY AT 24 HOURS POSTINFUSION FOR MILD OR MODERATE BLEEDS IN INDIVIDUALS WITH HEMOPHILIA A OR B AND INHIBITORS
Boggio, Lisa; (...); Escobar, Miguel
Meeting Abstract. 2023
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
Haemophilic arthropathy: basic protocols for clinical examination and imaging.
Querol, F.; (...); Perez-Alenda, S.
Article. 10.1097/MBC.0000000000001215. 2023
Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions
Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta
Meeting Abstract. 2024
HOW ARE SPANISH HEMOPHILIA NURSES UP TO DATED?
Garcia-Barcenilla, S.; (...); Bosch-Ferrando, P.
Meeting Abstract. 2023
Humanistic burden of haemophilia A without inhibitors: A cross-sectional analysis of the HemoLIFE study.
Alvarez-Roman, Maria Teresa; (...); Soto-Ortega, Inmaculada
Article. 10.1111/hae.15057. 2024
IMPACT OF INITIATION OF PROPHYLAXIS, SYNOVITIS AND FUNCTIONALITY ON JOINT HEALTH IN PATIENTS WITH HEMOPHILIA
Chimeno, A.; (...); Bonanad Boix, S.
Meeting Abstract. 2023
Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.
Jiménez-Yuste V; (...); Rodríguez-López M
Article. 10.1055/s-0044-1785525. 2024
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
Moderate haemophilia A: Recommendations from a Spanish panel of experts.
Álvarez Román MT; (...); López-Jaime FJ
Article. 10.1111/hae.15110. 2024
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments.
Ferre-Vallverdu, Mari; (...); Moscardo, Antonio
Article. 10.1016/j.thromres.2022.03.002. 2022
Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Pegcetacoplan: Real Life Experience
Vallejo, Carlos; (...); Vara, Miriam
Meeting Abstract. 10.1182/blood-2023-185570. 2023
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megias-Vericat, J. E.; (...); Poveda Andres, J. L.
Article. 10.1016/j.thromres.2022.06.001. 2022
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megias-Vericata, J. E.; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2023.11.023. 2023
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
Ettingshausen CE; (...); Windyga J
Article. 10.1177/20406207231184323. 2023
Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study.
Villas JMC; (...); Álvarez-Román MT
Letter. 10.1016/j.thromres.2024.109180. 2024
The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients.
Nunez, Ramiro; (...); Jimenez-Yuste, Victor
Article. 10.1055/s-0042-1757745. 2022
Thromboembolic hazard in hereditary hemorrhagic telangiectasia.
Asensi Canto, Pedro; (...); Bonanad Boix, Santiago
Article. 10.1002/jha2.471. 2022
Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study.
Bravo-Perez, Carlos; (...); Corral, Javier
Article. 10.1016/S2352-3026(24)00138-8. 2024